Currently out of the existing stock ratings of Kyle Rose, 174 are a BUY (85.29%), 30 are a HOLD (14.71%).

Kyle Rose

Work Performance Price Targets & Ratings Chart

Analyst Kyle Rose, currently employed at CANACCORD, carries an average stock price target met ratio of 54.08% that have a potential upside of 27.6% achieved within 177 days.

Kyle Rose’s has documented 425 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TELA, Tela Bio at 20-Mar-2025.

Wall Street Analyst Kyle Rose

Analyst best performing recommendations are on RSLS (RESHAPE LIFESCIENCES).
The best stock recommendation documented was for XENT (INTERSECT ENT) at 1/11/2021. The price target of $25 was fulfilled within 2 days with a profit of $2.78 (12.51%) receiving and performance score of 62.56.

Average potential price target upside

of $673750 (67.38%) on RSLS (RESHAPE LIFESCIENCES).
of $27.43 (13.03%) on PODD (INSULET).
of $26.15 (39.3%) on SIEN (SIENTRA).

ATEC Alphatec Holdings AXGN Axogen CFMS ConforMIS DXCM DexCom FNA Paragon 28 INMD InMode Ltd KRMD Repro Med Systems NUVA NuVasive PODD Insulet SIBN Si-Bone SIEN Sientra SPNE SeaSpine Holdings Corp SYK Stryker TELA Tela Bio XENT Intersect ENT ZBH Zimmer Biomet Holdings SKIN Beauty Health Co GMED Globus Medical MSON Misonix RSLS ReShape Lifesciences SENS Senseonics Holdings OBLN Obalon Therapeutics BVS Bioventus SNN Smith & Nephew SNATS ENOV Enovis Corp RBOT Vicarious Surgical

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matt Miksic (BARCLAYS)